JP2014530900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530900A5 JP2014530900A5 JP2014537760A JP2014537760A JP2014530900A5 JP 2014530900 A5 JP2014530900 A5 JP 2014530900A5 JP 2014537760 A JP2014537760 A JP 2014537760A JP 2014537760 A JP2014537760 A JP 2014537760A JP 2014530900 A5 JP2014530900 A5 JP 2014530900A5
- Authority
- JP
- Japan
- Prior art keywords
- tautomer
- compound
- imidazol
- amine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- VCHWGGQXHIBEEA-VIFPVBQESA-N 3-[(1r)-1-[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]ethyl]oxetan-3-amine Chemical compound C=1NC([C@H](C)C2(N)COC2)=NC=1C1=CC=C(OC(F)(F)F)C=C1 VCHWGGQXHIBEEA-VIFPVBQESA-N 0.000 claims 1
- ONVPCYBBFGHZSZ-LBPRGKRZSA-N 3-[(1r)-1-[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]propyl]oxetan-3-amine Chemical compound C=1NC([C@H](CC)C2(N)COC2)=NC=1C1=CC=C(OC(F)(F)F)C=C1 ONVPCYBBFGHZSZ-LBPRGKRZSA-N 0.000 claims 1
- WEAFAWYVJKPGDN-VIFPVBQESA-N 3-[(1r)-1-[5-[4-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]ethyl]oxetan-3-amine Chemical compound C=1NC([C@H](C)C2(N)COC2)=NC=1C1=CC=C(C(F)(F)F)C=C1 WEAFAWYVJKPGDN-VIFPVBQESA-N 0.000 claims 1
- VCHWGGQXHIBEEA-SECBINFHSA-N 3-[(1s)-1-[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]ethyl]oxetan-3-amine Chemical compound C=1NC([C@@H](C)C2(N)COC2)=NC=1C1=CC=C(OC(F)(F)F)C=C1 VCHWGGQXHIBEEA-SECBINFHSA-N 0.000 claims 1
- ONVPCYBBFGHZSZ-GFCCVEGCSA-N 3-[(1s)-1-[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]propyl]oxetan-3-amine Chemical compound C=1NC([C@@H](CC)C2(N)COC2)=NC=1C1=CC=C(OC(F)(F)F)C=C1 ONVPCYBBFGHZSZ-GFCCVEGCSA-N 0.000 claims 1
- WEAFAWYVJKPGDN-SECBINFHSA-N 3-[(1s)-1-[5-[4-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]ethyl]oxetan-3-amine Chemical compound C=1NC([C@@H](C)C2(N)COC2)=NC=1C1=CC=C(C(F)(F)F)C=C1 WEAFAWYVJKPGDN-SECBINFHSA-N 0.000 claims 1
- VCHWGGQXHIBEEA-UHFFFAOYSA-N 3-[1-[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]ethyl]oxetan-3-amine Chemical compound C1OCC1(N)C(C)C(NC=1)=NC=1C1=CC=C(OC(F)(F)F)C=C1 VCHWGGQXHIBEEA-UHFFFAOYSA-N 0.000 claims 1
- ONVPCYBBFGHZSZ-UHFFFAOYSA-N 3-[1-[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]propyl]oxetan-3-amine Chemical compound C1OCC1(N)C(CC)C(NC=1)=NC=1C1=CC=C(OC(F)(F)F)C=C1 ONVPCYBBFGHZSZ-UHFFFAOYSA-N 0.000 claims 1
- WEAFAWYVJKPGDN-UHFFFAOYSA-N 3-[1-[5-[4-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]ethyl]oxetan-3-amine Chemical compound C1OCC1(N)C(C)C(NC=1)=NC=1C1=CC=C(C(F)(F)F)C=C1 WEAFAWYVJKPGDN-UHFFFAOYSA-N 0.000 claims 1
- KOFTYPLPHYCLEM-UHFFFAOYSA-N 3-[[5-(4-chloro-3-methylphenyl)-1h-imidazol-2-yl]methyl]oxetan-3-amine Chemical compound C1=C(Cl)C(C)=CC(C=2N=C(CC3(N)COC3)NC=2)=C1 KOFTYPLPHYCLEM-UHFFFAOYSA-N 0.000 claims 1
- HIPVLIIHJJHFJK-UHFFFAOYSA-N 3-[[5-[4-(difluoromethoxy)phenyl]-1h-imidazol-2-yl]methyl]oxetan-3-amine Chemical compound N=1C(C=2C=CC(OC(F)F)=CC=2)=CNC=1CC1(N)COC1 HIPVLIIHJJHFJK-UHFFFAOYSA-N 0.000 claims 1
- ARCAJTAMUQLDKI-UHFFFAOYSA-N 3-[[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]methyl]oxan-3-amine Chemical compound N=1C(C=2C=CC(OC(F)(F)F)=CC=2)=CNC=1CC1(N)CCCOC1 ARCAJTAMUQLDKI-UHFFFAOYSA-N 0.000 claims 1
- QMSYRAZMYGWQJB-UHFFFAOYSA-N 3-[[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]methyl]oxetan-3-amine Chemical compound N=1C(C=2C=CC(OC(F)(F)F)=CC=2)=CNC=1CC1(N)COC1 QMSYRAZMYGWQJB-UHFFFAOYSA-N 0.000 claims 1
- JBKQPDYDZFNNCB-UHFFFAOYSA-N 3-[[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]methyl]oxolan-3-amine Chemical compound N=1C(C=2C=CC(OC(F)(F)F)=CC=2)=CNC=1CC1(N)CCOC1 JBKQPDYDZFNNCB-UHFFFAOYSA-N 0.000 claims 1
- FBZXNMLGHZYHND-UHFFFAOYSA-N 3-[[5-[4-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]methyl]oxetan-3-amine Chemical compound N=1C(C=2C=CC(=CC=2)C(F)(F)F)=CNC=1CC1(N)COC1 FBZXNMLGHZYHND-UHFFFAOYSA-N 0.000 claims 1
- AMAJNGRPSHOPRB-UHFFFAOYSA-N 4-[[5-[4-(trifluoromethoxy)phenyl]-1h-imidazol-2-yl]methyl]oxan-4-amine Chemical compound N=1C(C=2C=CC(OC(F)(F)F)=CC=2)=CNC=1CC1(N)CCOCC1 AMAJNGRPSHOPRB-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- -1 n- propyl Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 0 *C(C(*)(*)N)c1nc(-c2cc(S)c(*)cc2)c[n]1 Chemical compound *C(C(*)(*)N)c1nc(-c2cc(S)c(*)cc2)c[n]1 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161551628P | 2011-10-26 | 2011-10-26 | |
| US61/551,628 | 2011-10-26 | ||
| PCT/IB2012/055610 WO2013061205A2 (en) | 2011-10-26 | 2012-10-15 | Chemical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530900A JP2014530900A (ja) | 2014-11-20 |
| JP2014530900A5 true JP2014530900A5 (OSRAM) | 2015-12-03 |
| JP5946538B2 JP5946538B2 (ja) | 2016-07-06 |
Family
ID=47278356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537760A Expired - Fee Related JP5946538B2 (ja) | 2011-10-26 | 2012-10-15 | ナトリウムチャネルモジュレーターとして有用な（４−フェニルイミダゾール−２−イル）エチルアミン誘導体 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9079878B2 (OSRAM) |
| EP (1) | EP2771335A2 (OSRAM) |
| JP (1) | JP5946538B2 (OSRAM) |
| KR (1) | KR101586966B1 (OSRAM) |
| CN (1) | CN103906746B (OSRAM) |
| AP (1) | AP2014007579A0 (OSRAM) |
| AU (1) | AU2012328034B2 (OSRAM) |
| BR (1) | BR112014009102A2 (OSRAM) |
| CA (1) | CA2850925C (OSRAM) |
| CL (1) | CL2014000956A1 (OSRAM) |
| CO (1) | CO6940427A2 (OSRAM) |
| CR (1) | CR20140185A (OSRAM) |
| CU (1) | CU20140046A7 (OSRAM) |
| DO (1) | DOP2014000085A (OSRAM) |
| EA (1) | EA023375B1 (OSRAM) |
| EC (1) | ECSP14013324A (OSRAM) |
| GT (1) | GT201400079A (OSRAM) |
| IL (1) | IL232267A (OSRAM) |
| MD (1) | MD20140037A2 (OSRAM) |
| MX (1) | MX337469B (OSRAM) |
| NI (1) | NI201400031A (OSRAM) |
| PE (1) | PE20141682A1 (OSRAM) |
| PH (1) | PH12014500919A1 (OSRAM) |
| SG (1) | SG11201401032YA (OSRAM) |
| TN (1) | TN2014000147A1 (OSRAM) |
| UA (1) | UA109220C2 (OSRAM) |
| WO (1) | WO2013061205A2 (OSRAM) |
| ZA (1) | ZA201402281B (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014003064A (es) * | 2011-09-14 | 2014-05-07 | Dow Agrosciences Llc | Metodos y sistemas para formar acidos boronicos y sus intermedios. |
| SMT201800521T1 (it) | 2013-12-13 | 2018-11-09 | Vertex Pharma | Profarmaci di piridonammidi utili come modulatori di canali del sodio |
| KR102192572B1 (ko) | 2014-06-09 | 2020-12-18 | 삼성전자주식회사 | 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치 |
| CA2965509C (en) | 2014-10-24 | 2023-03-14 | Avectas Limited | Delivery across cell plasma membranes |
| WO2016134283A1 (en) | 2015-02-19 | 2016-08-25 | Purdue Pharma L.P. | Methods and compositions for decreasing gastric emptying |
| IS2977B (is) | 2015-02-23 | 2017-07-15 | Actavis Group Ptc Ehf. | Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni |
| US11827899B2 (en) | 2015-12-30 | 2023-11-28 | Avectas Limited | Vector-free delivery of gene editing proteins and compositions to cells and tissues |
| CA3029132A1 (en) * | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
| JP7548696B2 (ja) | 2016-07-06 | 2024-09-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛関連障害を処置するための物質及び方法 |
| WO2018213426A1 (en) | 2017-05-16 | 2018-11-22 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| WO2019014352A1 (en) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS |
| JP2021512935A (ja) | 2018-02-12 | 2021-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 疼痛を処置する方法 |
| AU2019372057A1 (en) | 2018-11-02 | 2021-05-27 | Merck Sharp & Dohme Llc | 2-amino-N-heteroaryl-nicotinamides as NAV1.8 inhibitors |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| US20240368135A1 (en) | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| US20250213555A1 (en) | 2021-06-04 | 2025-07-03 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| EP4347584A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| EP4346818B1 (en) | 2021-06-04 | 2025-12-03 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン |
| AU2023255558A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| KR20250005373A (ko) | 2022-04-22 | 2025-01-09 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| EP4511114A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| EP4511115A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3256486A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics Inc | Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management |
| CN115656380B (zh) * | 2022-11-09 | 2025-04-01 | 武汉海特生物创新医药研究有限公司 | 一种mtv对映异构体的hplc-uv检测方法 |
| CN120603815A (zh) | 2022-12-06 | 2025-09-05 | 沃泰克斯药物股份有限公司 | 钠通道的取代四氢呋喃调节剂的合成方法 |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
| WO2025231324A1 (en) * | 2024-05-02 | 2025-11-06 | Genep Inc. | Imidazole compounds and their use as sodium channel inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US7291641B2 (en) | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| TWI292316B (en) * | 1999-10-11 | 2008-01-11 | Sod Conseils Rech Applic | Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof |
| US7112366B2 (en) | 2001-01-05 | 2006-09-26 | The Ohio State University | Chemical monolayer and micro-electronic junctions and devices containing same |
| TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| FR2842808B1 (fr) * | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques |
| JP4173191B2 (ja) * | 2004-05-07 | 2008-10-29 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｈ３リガンドとして有用な３‐または４‐一置換フェノールおよびチオフェノール誘導体 |
| US7456164B2 (en) * | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| SG158921A1 (en) | 2004-10-27 | 2010-02-26 | Schering Corp | Compositions and methods for short interfering nucleic acid inhibition of nav1.8 |
| SI1963280T1 (sl) * | 2005-12-22 | 2016-02-29 | Newron Pharmaceuticals S.P.A. | 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov |
| DK2076508T3 (da) | 2006-10-18 | 2011-02-21 | Pfizer Prod Inc | Biaryl-ether-urinstof-forbindelser |
| CA2681572C (en) | 2007-03-23 | 2014-02-11 | Icagen, Inc. | Inhibitors of ion channels |
| KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
| US20100227872A1 (en) * | 2007-05-03 | 2010-09-09 | Mark Ian Kemp | Pyrazine derivatives |
| US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
-
2012
- 2012-10-15 US US14/351,893 patent/US9079878B2/en not_active Expired - Fee Related
- 2012-10-15 JP JP2014537760A patent/JP5946538B2/ja not_active Expired - Fee Related
- 2012-10-15 CN CN201280052591.6A patent/CN103906746B/zh not_active Expired - Fee Related
- 2012-10-15 PH PH1/2014/500919A patent/PH12014500919A1/en unknown
- 2012-10-15 AU AU2012328034A patent/AU2012328034B2/en not_active Ceased
- 2012-10-15 MX MX2014004738A patent/MX337469B/es active IP Right Grant
- 2012-10-15 KR KR1020147010826A patent/KR101586966B1/ko not_active Expired - Fee Related
- 2012-10-15 WO PCT/IB2012/055610 patent/WO2013061205A2/en not_active Ceased
- 2012-10-15 BR BR112014009102A patent/BR112014009102A2/pt active Search and Examination
- 2012-10-15 EA EA201490864A patent/EA023375B1/ru not_active IP Right Cessation
- 2012-10-15 MD MDA20140037A patent/MD20140037A2/ro not_active Application Discontinuation
- 2012-10-15 EP EP12794777.8A patent/EP2771335A2/en not_active Withdrawn
- 2012-10-15 CA CA2850925A patent/CA2850925C/en not_active Expired - Fee Related
- 2012-10-15 UA UAA201404440A patent/UA109220C2/uk unknown
- 2012-10-15 PE PE2014000605A patent/PE20141682A1/es not_active Application Discontinuation
- 2012-10-15 SG SG11201401032YA patent/SG11201401032YA/en unknown
- 2012-10-15 AP AP2014007579A patent/AP2014007579A0/xx unknown
-
2014
- 2014-03-27 ZA ZA2014/02281A patent/ZA201402281B/en unknown
- 2014-04-08 TN TNP2014000147A patent/TN2014000147A1/fr unknown
- 2014-04-14 CL CL2014000956A patent/CL2014000956A1/es unknown
- 2014-04-23 NI NI201400031A patent/NI201400031A/es unknown
- 2014-04-24 CU CU2014000046A patent/CU20140046A7/es unknown
- 2014-04-24 CR CR20140185A patent/CR20140185A/es unknown
- 2014-04-25 GT GT201400079A patent/GT201400079A/es unknown
- 2014-04-25 DO DO2014000085A patent/DOP2014000085A/es unknown
- 2014-04-25 EC ECSP14013324 patent/ECSP14013324A/es unknown
- 2014-04-27 IL IL232267A patent/IL232267A/en not_active IP Right Cessation
- 2014-04-28 CO CO14090473A patent/CO6940427A2/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530900A5 (OSRAM) | ||
| JP2013537203A5 (OSRAM) | ||
| JP2016538313A5 (OSRAM) | ||
| JP2013508279A5 (OSRAM) | ||
| JP2006524660A5 (OSRAM) | ||
| JP2016526576A5 (OSRAM) | ||
| JP2013512277A5 (OSRAM) | ||
| JP2014526501A5 (OSRAM) | ||
| JP2014520809A5 (OSRAM) | ||
| JP2009535307A5 (OSRAM) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2011529054A5 (OSRAM) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2009523760A5 (OSRAM) | ||
| JP2018536648A5 (OSRAM) | ||
| JP2013544276A5 (OSRAM) | ||
| JP2013544860A5 (OSRAM) | ||
| JP2014507477A5 (OSRAM) | ||
| JP2020512337A5 (OSRAM) | ||
| JP2009543795A5 (OSRAM) | ||
| RU2007101236A (ru) | Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей | |
| JP2010526819A5 (OSRAM) | ||
| JP2012530765A5 (OSRAM) | ||
| JP2017505293A5 (OSRAM) | ||
| JP2013506674A5 (OSRAM) |